- Associated Press•15 hours ago
The Cambridge, Massachusetts-based company said it had a loss of 7 cents per share. Losses, adjusted for non-recurring gains, came to 11 cents per share. The cancer drug company posted revenue of $127,000 ...
- Business Wire•15 hours ago
AVEO Oncology today reported financial results for the full year ended December 31, 2016 and provided a business update.
- Business Wire•yesterday
AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC
AVEO Oncology today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® , in advanced renal cell carcinoma .
AVEO : Summary for AVEO Pharmaceuticals, Inc. - Yahoo Finance
AVEO Pharmaceuticals, Inc. (AVEO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Ask||1.08 x 1000|
|Day's Range||0.80 - 0.87|
|52 Week Range||0.54 - 1.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.93|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|